Comparing combination therapy with orelabrutinib alone for CLL/SLL
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new treatment schedule that combines the drug orelabrutinib (a targeted therapy) with a fixed-cycle plan, compared with using orelabrutinib alone. This may help people with CLL/SLL who need treatment but haven't had standard therapy yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Your disease needs treatment, and you are either untreated or have not received a standard treatment yet.
- You are able to take care of yourself (Eastern Cooperative Oncology Group score 0-2).
- You have not had another cancer (other than CLL/SLL) in the past year, and your CLL/SLL has not transformed into a more aggressive lymphoma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill (orelabrutinib) combined with a standard chemotherapy regimen (called BG) as your first treatment for CLL or SLL. The goal is to see if this combination works well and is safe for people like you who have not been treated before.
This trial tests two new oral medications (ICP-248 and Orelabrutinib) together as a first treatment for people with CLL or SLL. The goal is to see if this combination works better than current options and is safe for newly diagnosed patients.
This trial tests if adding orelabrutinib (a targeted pill) to standard chemotherapy, with or without a stem cell transplant, works better for people with a new diagnosis of diffuse large B-cell lymphoma. It may help patients who have a higher risk of the lymphoma coming back.
This trial tests whether adding a targeted therapy called orelabrutinib to standard chemotherapy (R-CHOP) helps people with a specific type of fast-growing lymphoma (CD5-positive DLBCL). If you have this lymphoma and haven't had a BTK inhibitor before, this combination might work better than chemo alone.
This trial tests a new drug called orelabrutinib given with standard chemotherapy for a specific subtype of diffuse large B-cell lymphoma (DLBCL) called MCD. The treatment aims to improve outcomes and is followed by a maintenance phase with orelabrutinib alone.
This trial tests a new combination of drugs (orelabrutinib plus BR) compared to BR alone for people with newly diagnosed mantle cell lymphoma who have not had treatment before. It may be an option if you are older or not able to have a stem cell transplant.
Hear when a new CLL/SLL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.